Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Azelastine/Beclomethasone Nasal Spray
NCT04817800Phase 2Completed
- Sponsor
- Humanis
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azelastine hydrochloride + beclomethasone dipropionate in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Humanis. Primary endpoints: Maximum observed plasma concentration at 23 hours, Area under the plasma concentration versus time curve from time zero to last quantifiable concentration at 23 hours and 1 more. Started Mar 2021; status: completed.
02
Drugs
azelastine hydrochloride + beclomethasone dipropionate
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT04817800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817800.